[{"id":"61ed23cb-0c39-45f9-835d-557d807f6aa9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03921021","created_at":"2021-01-18T19:17:33.481Z","updated_at":"2024-07-02T16:35:41.743Z","phase":"Phase 2","brief_title":"Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma","source_id_and_acronym":"NCT03921021","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Telomelysin (suratadenoturev)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 07/20/2023","study_completion_date":" 07/20/2023","last_update_posted":"2023-07-27"}]